Skip to main content
SpringerLink
Log in

PTH: formulazioni disponibili e in fase di studio per il trattamento dell’ipoparatiroidismo

  • FARMACI INNOVATIVI
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Gardella TJ, Vilardaga JP (2015) International union of basic and clinical pharmacology. XCIII. The parathyroid hormone receptors—family B G protein–coupled receptors. Pharmacol Rev 67:310–337

    Article  CAS  Google Scholar 

  2. Potts JT, Tregear GW, Keutmann HT et al. (1971) Synthesis of a biologically active N-terminal tetratriacontapeptide of parathyroid hormone. Proc Natl Acad Sci USA 68:63–67

    Article  CAS  Google Scholar 

  3. Bollerslev J, Rejnmark L, Marcocci C et al. (2015) European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173(2):G1–20

    Article  CAS  Google Scholar 

  4. Winer KK (2019) Advances in the treatment of hypoparathyroidism with PTH 1-34. Bone 120:535–541

    Article  CAS  Google Scholar 

  5. Karpf DB, Pihl S, Mourya S et al. (2020) A randomized double-blind placebo-controlled first-in-human phase 1 trial of transcon PTH in healthy adults. J Bone Miner Res 35(8):1430–1440

    Article  CAS  Google Scholar 

  6. Mannstadt M, Clarke BL, Vokes T et al. (2013) Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1:275–283

    Article  CAS  Google Scholar 

  7. Shimizu M, Joyashiki E, Noda H et al. (2016) Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys. J Bone Miner Res 31(7):1405–1412

    Article  CAS  Google Scholar 

  8. Tamura T, Noda H, Joyashiki E et al. (2016) Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism. Nat Commun 7:1–14

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scuola di Specializzazione in Endocrinologia e Malattie del Metabolismo, Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italia

    Matteo Apicella & Laura Mazoni

  2. Unità di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italia

    Filomena Cetani

Authors
  1. Matteo Apicella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Mazoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Filomena Cetani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matteo Apicella.

Ethics declarations

Conflitto di interesse

Gli autori Matteo Apicella, Laura Mazoni e Filomena Cetani dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Nota della casa editrice

Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Apicella, M., Mazoni, L. & Cetani, F. PTH: formulazioni disponibili e in fase di studio per il trattamento dell’ipoparatiroidismo. L'Endocrinologo 22, 258–259 (2021). https://doi.org/10.1007/s40619-021-00870-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-021-00870-z

Search

Navigation